Boston Scientific (NYSE:BSX – Get Free Report) announced its quarterly earnings results on Wednesday. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04, Briefing.com reports. The firm had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. Boston Scientific had a return on equity of 16.80% and a net margin of 12.00%. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.53 earnings per share.
Boston Scientific Stock Performance
NYSE BSX opened at $74.95 on Friday. The business’s 50-day moving average price is $76.49 and its 200 day moving average price is $70.32. Boston Scientific has a twelve month low of $48.35 and a twelve month high of $79.43. The company has a market capitalization of $109.96 billion, a PE ratio of 62.98, a price-to-earnings-growth ratio of 2.47 and a beta of 0.78. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47.
Insider Buying and Selling
In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $77.30, for a total transaction of $539,785.90. Following the transaction, the executive vice president now directly owns 42,908 shares in the company, valued at $3,316,788.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $77.30, for a total value of $539,785.90. Following the transaction, the executive vice president now directly owns 42,908 shares in the company, valued at approximately $3,316,788.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Charles J. Dockendorff sold 3,946 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total value of $286,874.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 62,441 shares of company stock worth $4,624,453. 0.50% of the stock is owned by company insiders.
Analyst Ratings Changes
Check Out Our Latest Analysis on Boston Scientific
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Read More
- Five stocks we like better than Boston Scientific
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- MarketBeat Week in Review – 7/22 – 7/26
- There Are Different Types of Stock To Invest In
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How to Use the MarketBeat Dividend Calculator
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.